Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valrubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHN2 | P52757 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 6/20 | 0.62 |
| ▸ | BLM | P54132 | 6/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valrubicin SCHEMBL12556870 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL12825 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL15372178 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL20541443 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL4053249 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL1652790 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL29418969 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL22463650 | 0.99 | MEN1 (0.99) | MEN1THRBKMT2AHTTLMNA | |
| Valrubicin SCHEMBL28183048 | 0.98 | MEN1 (0.97) | MEN1THRBKMT2AHTTLMNA | |
| SCHEMBL13394009 | 0.96 | MEN1 (0.93) | MEN1THRBKMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 44395 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4744680-A1 | TARGETED CHEMICAL DRUG AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE OF TARGETED CHEMICAL DRUG | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727589-A1 | PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF | The Regents of the University of California (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727979-A2 | COMPOSITIONS AND METHODS FOR TARGETING EXTRACELLULAR DNA | Caris Science, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-6462017-B1 | THYMOSIN A1 IN CONJUNCTION WITH CHEMODRUG; MEDIATES LOSS OF APPETITE, LOSS OF SLEEP, FATIGUE, REDUCTION IN DAILY ACTIVITY, DECLINE IN OVERALL FEELING, DEPRESSION, NAUSEA AND VOMITING SIDE EFFECTS | SCICLONE PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| US-20020142050-A1 | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC. | 2002-10-03 | — | — | US | claimed |
| CN-1365274-A | Porous drug matrices and methods of making same | ACUSPHERE INC (US) | 2002-08-21 | — | — | CN | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001082949-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001072341-A2 | METHODS OF TREATING NEOPLASIA WITH COMBINATIONS OF TARGET CELL-SPECIFIC ADENOVIRUS, CHEMOTHERAPY AND RADIATION | CELL GENESYS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |